Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing Symptoms of Allergic Rhinitis

Inclusion Criteria

• •1. Men and women ≥ 18 years old
• •2. Inform consent
• •3. Beneficiaries of a social security scheme
• •4. Having documented persistent or intermittent allergic rhinitis for at least 2 years
• •5. In the respiratory environment allergen battery, at least one prick-test positive at selection (diameter \>3mm compared to the negative control), or prick-test or specific IgE assay less than 6 months old demonstrating an allergic response appropriate
• •6. Agreeing not to take anti-allergic drug treatment during the duration of the study except in case of aggravation of the disease
• •7. Having a smartphone or a computer allowing access to the application of seizure
• •To be eligible to be randomized, participants must have:
• •8. Used the nasal spray at least 2 times a day during the run-in, according to their answers on the application
• •9. A median VAS for the evaluation of the discomfort due to the symptoms of the selection at D-1 ≥ 50mm
• •1. Existence of links with any member of the study staff or the sponsor, or conflicts interests with the promoter
• •2. Known hypersensitivity or allergy to one of the components of the product tested
• •3. Contraindication to the use of a nasal spray
• •4. Respiratory pathology other than allergic rhinitis/rhino-conjunctivitis and asthma mild or moderate. People with severe asthma may be included if their asthma is controlled
• •5. Current treatment with systemic corticosteroids
• •6. Known pregnancy or positive urine pregnancy test at screening and/or at D0, or breastfeeding in progress
• •7. Participation in a clinical trial or other clinical investigation using a device medicine for the treatment or prevention of rhinitis or conjunctivitis